Loading...

SCNX SCIENTURE HOLDINGS INC Company Mergers 8-K Filing

SCNT

SCNX

SCIENTURE HOLDINGS INC

(SCNX)

2025 8-K

Investor Presentation Update

Annual Meeting Results

Share Offering Update

Share Offering Update

Leadership Changes

Nasdaq Compliance Notice

Loan Agreement Amendment

Bylaw Amendment

Debt Conversion Agreement

Equity Distribution Agreement

Stock Offering Details

Equity Offerings

Resignations and Appointments

Consulting Agreement

Management Changes

Exclusive Agreement

Director Resignations

Nasdaq Compliance Notice

Securities Agreement

Stock Conversion

Investor Presentation

Merger Agreement

Dividend Declaration

Director Appointment and Re...

Delisting Notice and Direct...

Non-Compliance with Nasdaq ...

Dividend and Agreements

Asset Purchase Agreement

Quarterly Earnings Reports

Merger of Equals

Delisting Notice

Late Filing of Quarterly Re...

Supplier Agreement

Private Placement

Dismissal of MaloneBailey, ...

Asset Purchase Agreement

Merger of Equals

Merger Agreement

Delisting Notice

Merger of Equals

Merger Agreement

Reverse Stock Split

Reverse Stock Split

Financial Results and Inves...

Financial Results and Inves...

Departure and Appointment o...

Termination of Offer Letter...

Material Definitive Agreeme...

Agreement to Sell Subsidiaries

Compensation Reduction and ...

Resignation and Appointment

External Links:

On March 17, 2025, Scienture Holdings Inc entered into a consulting agreement with Draper, Inc, agreeing to pay 100,000 restricted shares for investor relations and business development services, and on March 18, 2025, announced the upcoming launch of its product ArbliTM (losartan potassium) Oral Suspension.

AI Assistant

SCIENTURE HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.